Bipolar Depression vs Major Depression: Diagnosis and Treatment Differences
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
A person experiencing depression may describe the same symptoms whether their underlying diagnosis is bipolar disorder or major depressive disorder (MDD): persistent sadness, profound exhaustion, inability to enjoy ordinary activities, disrupted sleep, difficulty concentrating, feelings of worthlessness, or thoughts of death. The central distinction often cannot be seen in the current depressive episode. Clinicians must examine the entire history of mood episodes, particularly whether the person has ever experienced mania or hypomania. That distinction affects the diagnosis, the risks associated with some medicines, and the plan for preventing future episodes. The National Institute of Mental Health and the VA/DoD 2023 clinical guideline emphasize episode history.
Bipolar depression is a depressive episode occurring in someone with bipolar I or bipolar II disorder. Major depression, in everyday diagnostic language, usually refers to major depressive disorder, which involves major depressive episodes without a qualifying lifetime manic or hypomanic episode. The phrase "major depressive episode" describes a state that can occur within either disorder. It is possible to satisfy the full depressive-episode criteria in bipolar disorder without having major depressive disorder. NIMH's depression publication explains the clinical symptoms, while its bipolar publication explains elevated and depressed mood episodes.
This article compares the diagnostic reasoning and treatment implications for adults, including why a first depressive presentation can be difficult to classify. It addresses the roles of mood-stabilizing medication, antidepressants, psychotherapy, risk monitoring, and follow-up. A person's symptoms and online screening results alone cannot establish either diagnosis; decisions about medication require individualized clinical assessment.
For additional clinical context, see How Is Bipolar Disorder Diagnosed? Clinical Assessment Explained, Bipolar I vs Bipolar II: Differences in Episodes, Diagnosis, and Course and Bipolar Disorder vs Borderline Personality Disorder: How Clinicians Distinguish Them.
Bipolar Depression vs Major Depression: A Direct Comparison
The defining feature of bipolar disorder is a history of mania or hypomania. Bipolar I involves at least one manic episode; major depressive episodes are common but are not necessary for the diagnosis. Bipolar II involves at least one hypomanic episode and at least one major depressive episode without any manic episode. By contrast, MDD involves depressive episodes without a lifetime history that meets criteria for mania or hypomania. Diagnostic criteria also consider substance and medication effects, medical explanations, and functional consequences. See NIMH.
The depressive symptoms overlap substantially. A person with either condition may sleep too much or too little, lose energy, experience diminished motivation, or develop suicidal thoughts. Neither the intensity of sadness nor the presence of a particular sleep symptom identifies the diagnosis. Researchers have identified group-level differences, but no single symptom reliably classifies an individual patient. A systematic review published September 18, 2026 found that combinations of historical and clinical indicators are more useful than isolated features.
Treatment is where the distinction becomes especially consequential. Evidence-based psychotherapy and antidepressants have established roles in MDD care. Bipolar depression is treated with phase- and subtype-specific options that account for the possibility of mania or hypomania and the risk of mood destabilization. Antidepressant monotherapy is not recommended for bipolar I depression in major international guidelines, although selected adjunctive approaches and bipolar II circumstances require separate evaluation. See the CANMAT/ISBD 2023 evidence update and NICE guideline NG222 for MDD.
The long-term monitoring plan also differs. People with recurrent MDD need follow-up for depressive recurrence and treatment-related issues. People with bipolar disorders also need monitoring for emerging hypomania, mania, mixed features, disruption of sleep and daily rhythms, and the interaction between treatment and mood elevation. Both diagnoses can cause substantial functional impairment, and each deserves careful management. NICE CG185 addresses long-term bipolar treatment.
What Is a Major Depressive Episode?
A major depressive episode generally involves at least two weeks of sustained symptoms, including depressed mood or greatly reduced pleasure or interest, together with additional problems such as fatigue, altered sleep, changes in appetite or weight, impaired thinking and concentration, agitation or slowing, excessive guilt or worthlessness, and thoughts of death or suicide. Symptoms must represent a change from usual functioning and have sufficient frequency, severity, and clinical significance. Clinicians examine medical, medication-related, and other possible explanations. NIMH's depression overview provides the established clinical framework.
This is a description of an episode, not by itself a complete account of the lifelong disorder. A depressive episode occurring in bipolar II disorder may meet the exact same depressive symptom criteria as one occurring in MDD. The difference is established by the history of hypomania or mania, the broader diagnostic evaluation, and relevant exclusion criteria. The peer-reviewed review by Hirschfeld explains why the two can be so difficult to distinguish during a depressed presentation.
Depressive episodes can also have features such as anxious distress, melancholic features, atypical features, or psychotic symptoms. They may occur alongside substance use, physical illness, sleep disorders, trauma-related symptoms, or anxiety conditions. These features influence assessment and safety, but none proves bipolarity on its own. Psychiatric evaluation therefore asks what the symptoms mean in the context of the person's actual longitudinal history.
What Are Mania and Hypomania?
Mania involves a distinct period of abnormally elevated, expansive, or irritable mood and increased energy or activity, accompanied by a characteristic cluster of symptoms. A person may need substantially less sleep, speak much more rapidly, experience racing thoughts, feel unusually powerful or capable, initiate excessive projects, or take major financial, sexual, or other risks. DSM-based criteria ordinarily require at least one week, although a qualifying episode can be shorter when hospitalization is required. Marked impairment, need for hospitalization, or psychotic symptoms can distinguish mania from hypomania. See the NIMH bipolar guide.
Hypomania is also a distinct change in mood and energy or activity, noticeable in behavior and different from the person's usual state. Its DSM-based minimum duration is four consecutive days, and it does not involve the severity of impairment, need for hospitalization, or psychosis that defines mania. Hypomania may go unreported because the person associates it with confidence, sociability, productivity, or finally feeling better. Friends, partners, or relatives sometimes remember changed sleep needs, spending, activity, or speech more clearly than the person seeking help for depression. NIMH discusses these presentations.
Bipolar II is not a mild form of bipolar I. The distinction concerns whether the elevated episodes reach manic severity, and people with bipolar II can experience prolonged, profoundly disabling depression. Conversely, very severe depression can occur in MDD without any bipolar history. A clinician does not use severity alone as the deciding criterion. NICE CG185 reflects the need to identify the specific bipolar condition and episode.
A short burst of feeling happy, becoming irritated in an argument, or being productive after a good night's sleep is not a qualifying elevated episode. Clinicians examine the quality, duration, associated symptoms, observable behavior, and degree of departure from baseline. Changes related to drugs, alcohol, prescription medication, physical disease, or loss of sleep require careful differential assessment. The VA/DoD bipolar guideline addresses these questions.
Which Symptoms Can Raise Suspicion of Bipolar Depression?
Research studies find that earlier onset, repeated depressive episodes, bipolar family history, mixed symptoms, and certain psychotic or atypical presentations are more frequent among some bipolar-depression samples than among MDD samples. These are statistical associations that vary with population and research method. The 2026 systematic review by Niktabe and Massoubre examined 36 studies and provides a contemporary synthesis of historical clues relevant to primary care.
Sleep and energy changes
Both types of depression can bring insomnia, hypersomnia, and fatigue. A particularly useful question is whether a person has also experienced distinct periods of sleeping very little without feeling tired while energy and activity rose substantially. Reduced need for sleep during mood elevation is different from insomnia accompanied by exhaustion. A history of that pattern prompts further assessment; it is not a diagnosis on its own. See NIMH.
Mixed features and agitation
A depressive episode may include some symptoms associated with elevated mood, such as heightened energy, unusually rapid thoughts, or increased talkativeness. Clinicians may assess whether the formal criteria for mixed features are met. Mixed symptoms occur in mood disorders and can affect treatment planning, but they do not invariably establish bipolar disorder. CANMAT/ISBD urges caution with antidepressants where prominent mixed features or previous switching are present.
Hypersomnia and psychomotor slowing
Some comparative studies find higher average rates of hypersomnia, psychomotor slowing, or atypical symptoms in bipolar depressive populations. There is substantial overlap with MDD, and effects differ across samples, illness stage, and medication exposure. Feeling tired or sleeping much longer than usual should never be presented as a reliable diagnostic test. The Hirschfeld differential-diagnosis review summarizes the limits of these clinical clues.
Family history and age at onset
A first-degree relative with bipolar disorder, particularly in combination with recurrent depression beginning at a younger age, can increase suspicion and justify a more detailed interview. Most individual risk factors have limited specificity, and absence of known family history does not exclude bipolar disorder. The 2026 systematic review supports a combined appraisal of family and episode histories.
Why Bipolar Depression Is Sometimes Initially Called Major Depression
Depression is often the symptom that brings a person to a doctor. Past hypomania may have felt useful, pleasant, or ordinary, so the person may not describe it as an illness. At an early point in someone's life, a qualifying elevated episode may not have occurred yet. In other cases, a very short clinical appointment concentrates on current low mood without enough time to reconstruct past periods of activation. These pathways explain why some diagnoses are revised as additional evidence emerges. Hirschfeld reviews diagnostic delay and overlap.
The opposite mistake is possible, too. Chronic irritability, quick emotional reactions, attention problems, anxiety, impulsivity, and insomnia are not synonymous with mania or hypomania. ADHD, borderline personality disorder, trauma-related conditions, substance use, thyroid conditions, other medical causes, and sleep problems may need evaluation. The distinction depends on discrete mood-episode patterns as well as enduring traits, context, developmental history, and alternative explanations. See VA/DoD 2023.
A previously established MDD diagnosis may be appropriately reconsidered if a person later develops a manic episode or a convincing hypomanic history becomes available. Diagnosis follows the best current clinical evidence. Revision should guide treatment safety and follow-up rather than imply that the prior depressive suffering was somehow invalid.
How Clinical Assessment Actually Works
A clinician usually begins by constructing a mood timeline. Questions include the age of the first depression, number of episodes, duration, recovery between episodes, hospitalizations, family history, and any periods of substantially increased energy or activity. Specific questions probe decreased need for sleep, speech speed, racing thoughts, confidence, irritability, unusual goals, spending, risky behavior, and changes that other people noticed. The interviewer also assesses how episodes affected relationships, employment, school, finances, and self-care. NIMH and VA/DoD support this longitudinal approach.
With the person's consent, information from relatives or partners and previous medical records can help reconstruct episodes that were missed or forgotten. A review of prescriptions, antidepressant and stimulant exposures, alcohol and other substances, physical illness, sleep disturbance, and other psychiatric symptoms is also important. Clinicians evaluate current suicide risk, agitation, psychosis, mixed features, and impairment. A single visit may not reveal the complete pattern; appropriately scheduled follow-up is part of assessment.
Do the MDQ or HCL-32 settle the diagnosis?
The Mood Disorder Questionnaire and Hypomania Checklist are screening tools that identify experiences warranting closer questioning. Their sensitivity and specificity vary with care setting and bipolar subtype. A positive result is not a formal diagnosis, and a negative result cannot rule out bipolar II when hypomanic experiences are poorly recalled or underreported. The differential-diagnosis review discusses why screening and diagnosis should remain distinct.
Can laboratory or brain-imaging tests distinguish the conditions?
No routine biomarker, genetic panel, blood test, brain scan, or artificial-intelligence classifier is clinically validated as an independent test for bipolar depression versus MDD. Laboratory investigations may be useful for medical differential diagnosis or drug monitoring, and research continues to study biological patterns. The decisive clinical work remains careful interviewing and longitudinal follow-up. NIMH describes current diagnostic practice.
How is a first depressive episode evaluated?
At a first presentation, the clinician may have clear evidence of a major depressive episode but insufficient history to establish whether bipolar disorder will become apparent later. Current symptoms still deserve appropriate treatment. Follow-up should revisit sleep and activity changes, possible medication-induced activation, family history, and any new information about previous episodes. The 2026 systematic review emphasizes the diagnostic value of longitudinal indicators in general practice.
Treatment Differences: MDD, Bipolar I Depression, and Bipolar II Depression
Treatment evidence is diagnosis- and phase-specific. A medicine proven for acute mania may lack adequate evidence for bipolar depression; a medicine useful for bipolar depression may have a different role in maintenance; and antidepressant studies in MDD do not automatically predict safety or efficacy in bipolar I or II. Choosing treatment requires the current episode, previous response, medical history, adverse effects, prior mood switching, pregnancy potential, and the individual's preferences. See CANMAT/ISBD 2023 and VA/DoD 2022 MDD.
Major depressive disorder
Evidence-based care for MDD includes structured psychotherapy—such as cognitive behavioral therapy, behavioral activation, or interpersonal psychotherapy—and, for selected situations, antidepressant medications. Some people benefit from psychotherapy alone, whereas others benefit from medication or combined treatment. Severity, duration, previous treatment, personal preference, safety, and access shape the plan. NICE NG222 differentiates options for less severe and more severe depression and supports shared decision-making.
When antidepressant medication is indicated, an SSRI is among commonly considered options, while other drug classes may suit certain patients. Benefits are weighed against adverse effects, interactions, sexual dysfunction, sleep or gastrointestinal symptoms, changes in agitation or suicidal thinking, and discontinuation effects. Clinicians review progress and adjust care if improvement is inadequate. The VA/DoD MDD guideline provides treatment recommendations and an approach to measurement-based follow-up.
People with severe or treatment-resistant MDD may need specialty care and treatments beyond first-line medication or psychotherapy, including ECT in specific circumstances. The suitability of such treatments depends on clinical presentation and risk. They are neither a diagnostic test for bipolar disorder nor a reason to change established medication without specialist supervision.
Bipolar I depression
In the 2023 CANMAT/ISBD update, recommended first-line strategies for acute bipolar I depression include quetiapine, lithium, lamotrigine, and lurasidone in specified regimens, with the exact ranking and whether an agent is combined with other treatment depending on the recommendation. Other options appear in later lines or newer evidence, and different national guidelines may vary. Clinicians distinguish acute antidepressant efficacy from protection against future mania or depressive recurrence. NICE CG185 provides alternative national algorithms.
Antidepressant monotherapy is not recommended for bipolar I depression by major guidelines. Particular caution applies when there is a history of antidepressant-associated mania, current mixed symptoms, or recent rapid cycling. A history of full mania fundamentally changes the balance of acute treatment and long-term protection. The existence of several drug options does not mean they have equivalent safety, metabolic effects, monitoring requirements, or evidence across every episode phase.
Bipolar II depression
Bipolar II requires its own treatment reasoning. The CANMAT/ISBD 2023 evidence update identifies quetiapine as a first-line acute option and lists lithium, lamotrigine, and certain other approaches at different evidence levels. Some antidepressants may be considered in selected nonmixed bipolar II depressive episodes after specialist assessment and risk review. Evidence in bipolar II is often more limited than in bipolar I, so clinicians should not transfer results indiscriminately.
Neither the presence of hypomania nor the absence of past full mania makes bipolar II depression unimportant. Recurrent depression, functional losses, self-harm risk, and medication tolerability all influence care. Individualization remains central, particularly where the history of mood elevation is uncertain or previous treatment appeared to trigger activation.
Antidepressants: Why the Risk-Benefit Balance Changes
Antidepressants are among the accepted treatments for MDD. In bipolar depression, evidence of antidepressant benefit is more heterogeneous, and some patients may experience treatment-emergent mania, hypomania, or mixed symptoms. Risk depends on the drug, subtype, history, other medication, and the individual's course. CANMAT/ISBD advises against bipolar I antidepressant monotherapy and recommends caution in people with previous switching, mixed features, or recent rapid cycling.
The landmark STEP-BD randomized trial found that adding standard antidepressants to a mood-stabilizing regimen did not improve the study's primary durable-recovery outcome compared with placebo. That result should not be extended to every antidepressant, bipolar subtype, or trial design, but it undermines the assumption that evidence from MDD always translates into bipolar depression. Some adjunctive or selected bipolar II strategies have separate, more limited evidence and remain matters for specialist judgment.
Developing a sudden reduced need for sleep, unusually high energy, rapid speech, risky decisions, extreme irritability, or psychosis while taking an antidepressant warrants prompt clinical evaluation. These experiences are not automatically proof of bipolar disorder, and medications should not be started, stopped, or adjusted independently. In a clinical context, NICE CG185 addresses management of emerging elevated symptoms during antidepressant treatment.
Medication Safety and Monitoring
Lithium is used for bipolar disorder, especially long-term treatment and selected depressive presentations, but its benefits come with a need for blood-level monitoring and periodic kidney and thyroid assessment. Dehydration, significant intercurrent illness, and interactions with some anti-inflammatory drugs, diuretics, and blood-pressure medications can alter lithium levels. New vomiting, significant tremor, poor coordination, or confusion may require urgent medical assessment. The NICE bipolar guideline details monitoring and important interactions.
Lamotrigine has evidence in bipolar depressive and maintenance strategies but is not an established treatment for acute mania. Initiation and dose changes must follow clinical instructions because serious skin reactions, including Stevens–Johnson syndrome, are possible. Any new rash warrants immediate prescriber advice, particularly if there is fever or mucosal involvement. Medication interactions can affect dosing and risk. See NICE CG185.
Valproate may be considered for certain mania and maintenance presentations but has major pregnancy-related and reproductive safety concerns. Current jurisdiction-specific restrictions and pregnancy-prevention requirements can apply. It is not a universally suitable treatment for bipolar depression or MDD, and changes require specialist advice. The NICE bipolar recommendations cover key precautions.
Second-generation antipsychotics differ markedly by specific drug. Depending on the agent, monitoring may involve weight, glucose or A1c, lipids, blood pressure, movement symptoms, sedation, and cardiovascular or other drug-specific risks. Evidence for treating mania is not automatically evidence for treating bipolar depression. The VA/DoD bipolar guideline emphasizes a treatment-specific risk-benefit review.
In MDD, antidepressant monitoring also considers tolerability, activation, suicidality, interactions, and withdrawal symptoms. A gradual, supervised discontinuation plan may be needed. This article provides no individualized medication recommendation or dosing instructions. See NICE NG222.
Psychotherapy and Recovery: Shared Methods, Different Emphases
CBT, behavioral activation, interpersonal psychotherapy, and other structured treatments can address depressive symptoms in MDD. Bipolar-specific care often adds psychoeducation, adapted CBT, family-focused therapy, and interpersonal and social rhythm approaches as adjuncts to medical management. Evidence depends on intervention, population, and phase. CANMAT/ISBD and NICE CG185 address bipolar psychosocial treatment; NICE NG222 addresses MDD psychotherapy.
In bipolar care, the treatment plan may pay particular attention to early signs of hypomania or mania, regular sleep-wake timing, social rhythms, medication coordination, and family communication. In MDD, treatment frequently focuses on withdrawing from activities, negative expectations, relationships, problem-solving, and restoring daily function. Both approaches can address anxiety, trauma, work, relationships, or disability in an individualized way. Appropriate psychotherapy supports, rather than replaces, medication and emergency interventions when these are clinically indicated.
A diagnosis does not determine the limits of a person's future. Recovery can include symptom improvement, meaningful social participation, employment or education, and personal agency. Functional improvement is a treatment outcome alongside changes in symptom scales. NICE CG185 and NICE NG222 address long-term management.
Relapse Prevention and Long-Term Follow-Up
Bipolar follow-up monitors possible depressive recurrence and emerging manic or hypomanic symptoms. A collaborative plan can identify early warning signs, sleep and activity changes, medication issues, and whom to contact before symptoms become severe. Longer-term treatment choices reflect previous episode frequency, past effectiveness, tolerability, and practical monitoring burdens. NICE CG185 addresses prevention and regular review.
People with recurrent MDD also benefit from relapse planning, including recognizing residual depressive symptoms, using psychological skills, evaluating the continuing role of antidepressants, and reviewing adverse effects. The maintenance decision depends on the person's history and preferences rather than a universal fixed duration. NICE NG222 gives specific recommendations for preventing relapse.
A mood diary may be helpful when it records sleep, energy, behavior, function, and treatment changes alongside mood. It cannot establish a bipolar diagnosis on its own. Sleep regularity, social support, early follow-up, and treatment collaboration may be useful in both conditions; no single daily-life practice replaces the evidence-based treatment needed for a severe episode.
When Depression Requires Urgent Help
Suicidal intent or plans, inability to remain safe, psychosis, severe mania, or dangerous impairment in judgment require urgent professional assessment regardless of diagnosis. If a person is in immediate danger, contact emergency services. In the United States, call or text 988 for crisis support; elsewhere use the appropriate local emergency or crisis services. NICE NG222 addresses assessment and management of suicide risk, and VA/DoD bipolar guidance covers clinical triage.
Someone previously diagnosed with MDD who suddenly needs almost no sleep yet feels highly energized, becomes intensely disinhibited, or develops hallucinations or delusions should receive timely reassessment. These symptoms may change urgent treatment needs. In all cases, safety and current clinical presentation take precedence over resolving an online diagnostic question.
Adolescents, Older Adults, Pregnancy, and Postpartum Care
In children and adolescents, clinicians need developmentally sensitive assessment of episodes and alternative explanations, including ADHD, chronic irritability, medical and substance factors, and family and school functioning. Adult medication trials cannot automatically establish effectiveness or safety for young people. The CANMAT/ISBD update includes distinct evidence for youth.
Pregnancy planning, pregnancy, and the postpartum period require specialized balancing of maternal mental health, relapse risk, fetal or infant exposure, and medication risks. Valproate poses serious reproductive hazards. A history of mania, hypomania, or postpartum psychosis is highly relevant to assessment, but a postpartum depressive episode alone is not proof of bipolar disorder. Stopping an established medication abruptly can also be hazardous; decisions belong in a coordinated clinical plan. NICE CG185 provides relevant guidance.
In older adults, polypharmacy, renal and thyroid conditions, neurological illness, and medical comorbidity may complicate both differential diagnosis and medication choice. New mood elevation appearing for the first time late in life warrants careful investigation of medical and substance-related causes. VA/DoD 2023 supports medical and psychiatric assessment together.
Misconceptions That Can Distort the Diagnosis
The first misconception is that bipolar depression must be more severe than unipolar depression. Either diagnosis can produce profound disability, psychotic symptoms, or suicidal thoughts. Severity guides urgency and treatment intensity; the lifetime course guides diagnosis. NIMH distinguishes episode categories.
The second misconception is that fast mood changes automatically establish bipolar disorder. Clinical mania and hypomania require a coherent episode pattern with changes in mood and energy or activity and relevant duration and symptoms. Stress, ADHD, trauma, personality patterns, substances, sleep loss, and other conditions can also produce emotional changes. VA/DoD supports a broad differential assessment.
The third misconception is that responding to an antidepressant establishes MDD. Treatment response cannot independently identify the underlying diagnosis. People with bipolar disorder may improve with some antidepressant-containing regimens, while people with MDD may respond poorly to several medications. The CANMAT/ISBD update evaluates evidence according to diagnosis, treatment regimen, and episode phase.
Finally, neither an online screening score nor a brain scan can replace the clinical history. Symptom scales provide useful information for discussion, not a definitive psychiatric label. The 2026 systematic review illustrates the need to combine multiple sources of clinical evidence.
Questions to Bring to Your Clinician
If you are being treated for depression and want to clarify whether bipolar disorder has been considered, ask for a review of your lifetime mood history. It can help to note the approximate timing of episodes, whether you ever needed unusually little sleep while feeling energized, changes that other people noticed, significant decisions made during elevated periods, any medication-related activation, past hospitalizations, and family history. An agreed account from a family member or partner can help when memories are incomplete.
Useful questions include how the current diagnosis was established, which alternative diagnoses remain plausible, what findings would change the treatment plan, and how mood elevation will be monitored if antidepressants are prescribed. Ask which medication risks, laboratory tests, early warning signs, crisis contacts, and follow-up schedule matter in your situation. Discuss any concerns before changing a prescription. The VA/DoD guideline emphasizes shared planning and safety.
Frequently Asked Questions
Can bipolar depression occur without a full manic episode?
Yes. Bipolar II disorder involves hypomania and major depression but no full manic episode. Bipolar I requires a manic episode, although depression commonly occurs. When there is no history of mania or hypomania, clinicians evaluate MDD and other possibilities without assuming bipolarity. See NIMH.
Can major depressive disorder later be reclassified as bipolar disorder?
Yes. Someone may first receive a diagnosis during depression and only later experience or disclose a clinically qualifying manic or hypomanic episode. New information can warrant a revised diagnosis. The earlier depressive experience remains clinically significant. The Hirschfeld review covers this problem.
Is there a symptom that proves bipolar depression?
No. Even symptoms that appear more often in particular research groups do not reliably diagnose an individual. A comprehensive assessment considers longitudinal episode history, family history, impairment, substances, and medical causes. See the 2026 systematic review.
Is antidepressant medication always unsafe in bipolar II depression?
The role of antidepressants depends on the bipolar subtype, the current episode, mixed symptoms, previous switching, available alternatives, and professional monitoring. Some selected bipolar II strategies appear in clinical guidelines, but this is not equivalent to routine antidepressant treatment for MDD or recommended monotherapy for bipolar I depression. See CANMAT/ISBD.
Do all patients with MDD need antidepressants?
No. Evidence-based psychotherapies, combined approaches, and other treatment options can be appropriate depending on severity, preference, safety, and treatment history. NICE NG222 distinguishes treatment choices by severity.
Can an online bipolar test or brain scan choose the medication?
No. Neither a self-report test nor a scan establishes a complete diagnosis or determines an individualized medication plan. Clinicians review symptoms, full history, risks, other conditions, monitoring needs, and patient preferences. See VA/DoD.
Related Articles
References
Hirschfeld, R. M. A. (2014). Differential diagnosis of bipolar disorder and major depressive disorder. Journal of Affective Disorders, 169(Suppl. 1), S12–S16. PubMed.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. DOI.
National Institute for Health and Care Excellence. (2014; updated). Bipolar disorder: Assessment and management (CG185). Official guideline.
National Institute for Health and Care Excellence. (2022; updated). Depression in adults: Treatment and management (NG222). Official guideline.
National Institute of Mental Health. (n.d.). Bipolar disorder. Official publication.
National Institute of Mental Health. (n.d.). Depression. Official publication.
Niktabe, D. S., & Massoubre, C. (2026). Distinguishing bipolar disorder from unipolar depression in general practice: A systematic review. European Journal of General Practice, 32(1), 2733396. DOI.
Sachs, G. S., et al. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356, 1711–1722. DOI.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2022). VA/DoD clinical practice guideline for the management of major depressive disorder. Official guideline.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of bipolar disorder. Official guideline.